{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:36:45Z","timestamp":1791283005186,"version":"4.1.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1097\/cco.0000000000000047","type":"journal-article","created":{"date-parts":[[2014,1,23]],"date-time":"2014-01-23T09:35:33Z","timestamp":1390469733000},"page":"159-164","source":"Crossref","is-referenced-by-count":38,"title":["Heat shock protein 90 inhibitors in non-small-cell lung cancer"],"prefix":"10.1097","volume":"26","author":[{"given":"Rathi N.","family":"Pillai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh S.","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210128","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/sj.bjc.6605066","article-title":"Targeting HSP90 for cancer therapy.","volume":"100","author":"Mahalingam","year":"2009","journal-title":"Br J Cancer"},{"key":"R2-6-20210128","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S1470-2045(13)70169-4","article-title":"Inhibition of HSP90 molecular chaperones: moving into the clinic.","volume":"14","author":"Garcia-Carbonero","year":"2013","journal-title":"Lancet Oncol"},{"key":"R3-6-20210128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013.","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"R4-6-20210128","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1200\/JCO.2010.30.8338","article-title":"Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.","volume":"28","author":"Sequist","year":"2010","journal-title":"J Clin Oncol"},{"key":"R5-6-20210128","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1038\/onc.2010.625","article-title":"The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.","volume":"30","author":"Normant","year":"2011","journal-title":"Oncogene"},{"issue":"Suppl","key":"R6-6-20210128","doi-asserted-by":"crossref","first-page":"abstr7516","DOI":"10.1200\/jco.2011.29.15_suppl.7516","article-title":"Safety and activity of IPI-504 (retaspimycin hydrochloride) and docetaxel in pretreated patients (pts) with metastatic non-small-cell lung cancer (NSCLC).","volume":"29","author":"Riely","year":"2011","journal-title":"J Clin Oncol"},{"key":"R7-6-20210128","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1158\/1535-7163.MCT-11-0755","article-title":"Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.","volume":"11","author":"Ying","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"R8-6-20210128","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1158\/1078-0432.CCR-11-2967","article-title":"Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small-cell lung cancer.","volume":"18","author":"Shimamura","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R9-6-20210128","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s10637-011-9790-6","article-title":"Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small-cell lung cancer models.","volume":"30","author":"Proia","year":"2012","journal-title":"Invest New Drugs"},{"key":"R10-6-20210128","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1158\/1535-7163.MCT-12-0615","article-title":"Targeting KRAS-mutant non-small-cell lung cancer with the Hsp90 inhibitor ganetespib.","volume":"11","author":"Acquaviva","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"R11-6-20210128","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1158\/1078-0432.CCR-12-3381","article-title":"A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small-cell lung cancer.","volume":"19","author":"Socinski","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"Suppl","key":"R12-6-20210128","doi-asserted-by":"crossref","first-page":"abstr3094","DOI":"10.1200\/jco.2012.30.15_suppl.3094","article-title":"A phase I and pharmacokinetic study of multiple schedules of ganetespib (STA-9090), a heat shock protein 90 inhibitor, in combination with docetaxel for subjects with advanced solid tumor malignancies.","volume":"30","author":"Kauh","year":"2012","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"R13-6-20210128","doi-asserted-by":"crossref","first-page":"CRA8007","DOI":"10.1200\/jco.2013.31.15_suppl.cra8007","article-title":"A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1).","volume":"31","author":"Ramalingam","year":"2013","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"R14-6-20210128","first-page":"S139","article-title":"GALAXY-1: randomized phase II study of docetaxel with or without ganetespib in advanced lung adenocarcinoma - results in biomarker sub-groups and all adenocarcinoma patients.","volume":"8","author":"Ramalingam","year":"2013","journal-title":"J Thorac Oncol"},{"key":"R15-6-20210128","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1158\/1078-0432.CCR-12-3404","article-title":"First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors.","volume":"19","author":"Sessa","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"Suppl 2","key":"R17-6-20210128","first-page":"S596","article-title":"A phase II study of Hsp90 inhibitor AUY922 and erlotinib (E) in patients with EGFR-mutant lung cancer and acquired resistance to EGFR tyrosine kinase inhibitors.","volume":"8","author":"Yu","year":"2013","journal-title":"J Thorac Oncol"},{"issue":"Suppl 2","key":"R18-6-20210128","first-page":"S914","article-title":"A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation.","volume":"8","author":"Nogova","year":"2013","journal-title":"J Thorac Oncol"},{"key":"R19-6-20210128","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1349-7006.2011.02191.x","article-title":"The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small-cell lung cancer.","volume":"103","author":"Graham","year":"2012","journal-title":"Cancer Sci"},{"issue":"Suppl 2","key":"R20-6-20210128","first-page":"S464","article-title":"The Hsp90 inhibitor, AT13387, displays single agent activity in erlotinib-sensitive and -resistant models of EGFR-activated NSCLC.","volume":"8","author":"Hearn","year":"2013","journal-title":"J Thorac Oncol"},{"issue":"Suppl 2","key":"R21-6-20210128","first-page":"S163","article-title":"Combining the Hsp90 inhibitor, AT13387, with crizotinib improves response in an ALK positive model of NSCLC.","volume":"8","author":"Smyth","year":"2013","journal-title":"J Thorac Oncol"},{"issue":"Suppl","key":"R22-6-20210128","doi-asserted-by":"crossref","first-page":"abstr3028","DOI":"10.1200\/jco.2012.30.15_suppl.3028","article-title":"First-in-human phase I study: results of a second-generation nonansamycin heat shock protein 90 (HSP90) inhibitor AT13387 in refractory solid tumors.","volume":"30","author":"Mahadevan","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:55:27Z","timestamp":1620950127000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201403000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000047","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}